Cluster Health & Mission Cancer Brokerage Event

28 Sept 2026 | Brussels, Belgium

Register
Register
Register

Project cooperationUpdated on 3 September 2026

Organ on chips, organoids and other NAMs for biomedical research

Business Development Manager, PharmD, MPH at Leitat Technological Center

Barcelona, Spain

About

  1. Organ-on-chip contribution:
    • Design, prototype ad upscale microfluidics/organ-on-chip devices using tailored matrices and hydrogels, cell types, and configurable architectures that support organ-level development and function.
    • Adding gravitational and pressurized perfusion systems to create different levels of complexity.
    • Sensing integration, detection of surveillance, anticipation of events, correction of processes in culture, can be added to improve the design.
    • Our platforms enable the generation of both healthy and pathological models to evaluate drug safety and efficacy across multiple organs and diseases. We have colorectal cancer model, liver, lung and gut, but are open to consider development of different organs /indications.
    • The models can be more personalized with cell monitoring, viability and cytotoxicity assessment, TEER permeability. They can also be coupled with advanced detection of cell markers, ECM components, ions, pH, metabolites, and cytokines.
    • Finally, we can create digital-twin technologies of the organ on chip system
    • We can use robotics to automate the platform and manipulate the hydrogels. This way we can think about a standardised platform more aligned with future regulations.  

  2. Organoids and 2D models:
    We can also develop various in vitro models from iPSCs, such as:
    • 3D organoid cultures (we can also consider other indications): Corneal, Intestinal, Brain, Pancreatic, Lung
    • 2D cultures (since we can differentiate iPSCs into the three germ layers, we could also consider differentiating them into other relevant cell types): Motor neurons, Cardiomyocytes, Hepatocytes, Pancreatic cells

  3. Bioreactors and biosensors for in vitro models

  4. Bioprinted tissue constructs

  5. Virtual Twins

  6. Advanced in vitro model muscle contraction (patented technology)

Topic

  • Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
  • Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Type

  • Partner seeks Consortium/Coordinator

Similar opportunities